2023
Early VTE prophylaxis in severe traumatic brain injury: A propensity score weighted EAST multicenter study
Ratnasekera A, Kim D, Seng S, Jacovides C, Kaufman E, Sadek H, Perea L, Monaco C, Shnaydman I, Lee A, Sharp V, Miciura A, Trevizo E, Rosenthal M, Lottenberg L, Zhao W, Keininger A, Hunt M, Cull J, Balentine C, Egodage T, Mohamed A, Kincaid M, Doris S, Cotterman R, Seegert S, Jacobson L, Williams J, Whitmill M, Palmer B, Mentzer C, Tackett N, Hranjec T, Dougherty T, Morrissey S, Donatelli-Seyler L, Rushing A, Tatebe L, Nevill T, Aboutanos M, Hamilton D, Redmond D, Cullinane D, Falank C, McMellen M, Duran C, Daniels J, Ballow S, Schuster K, Ferrada P. Early VTE prophylaxis in severe traumatic brain injury: A propensity score weighted EAST multicenter study. Journal Of Trauma And Acute Care Surgery 2023, 95: 94-104. PMID: 37017458, DOI: 10.1097/ta.0000000000003985.Peer-Reviewed Original ResearchConceptsVenous thromboembolism eventsIntracranial hemorrhage expansionSevere traumatic brain injuryTraumatic brain injuryVTE prophylaxisPropensity scoreBrain injuryHead CTHigh riskHigh incidenceAdult patients 18 yearsLevel II trauma centerEarly VTE prophylaxisEAST multicenter studyPatients 18 yearsUnivariate logistic regression modelMulti-center analysisLogistic regression modelsTiming of initiationProphylaxis initiationThromboembolism eventsPredictors of interestClinical characteristicsPrimary outcomeRetrospective review
2019
The association between racial and socioeconomic discrimination and two stages of alcohol use in blacks
Haeny AM, Sartor CE, Arshanapally S, Ahuja M, Werner KB, Bucholz KK. The association between racial and socioeconomic discrimination and two stages of alcohol use in blacks. Drug And Alcohol Dependence 2019, 199: 129-135. PMID: 31048089, PMCID: PMC6684260, DOI: 10.1016/j.drugalcdep.2019.02.026.Peer-Reviewed Original ResearchConceptsTiming of initiationRisk factorsUnadjusted modelsProportional hazards regression analysisAlcohol useFirst drinkHigh-risk family studyHazards regression analysisPsychosocial risk factorsAlcohol use disorderReligious service attendanceRobust risk factorSocial supportService attendanceUse disordersPrevention programsTelephone interviewsSubstance useAlcohol initiationFemale offspringMaternal experienceFamily studiesRegression analysis
2018
Caffeine controversies
Gentle S, Travers C, Carlo W. Caffeine controversies. Current Opinion In Pediatrics 2018, 30: 177-181. PMID: 29346141, DOI: 10.1097/mop.0000000000000588.Peer-Reviewed Original ResearchConceptsApnea of prematurityBronchopulmonary dysplasiaPreterm infantsEvidence of bronchopulmonary dysplasiaCaffeine usePatent ductus arteriosusRate of motor impairmentCaffeine therapyRate of deathRandomized Controlled TrialsDuctus arteriosusNeurodevelopmental impairmentTherapy initiationNeonatal careCaffeine groupFollow-upTiming of initiationInfantsPretermCaffeineDoseMotor impairmentRisk reductionImpairmentApnea
2017
A Novel Risk Score to Predict the Need for Nutrition Support After Cardiac Surgery
Ohkuma R, Crawford T, Brown P, Grimm J, Magruder J, Kilic A, Suarez-Pierre A, Snyder S, Wood J, Schneider E, Sussman M, Whitman G. A Novel Risk Score to Predict the Need for Nutrition Support After Cardiac Surgery. The Annals Of Thoracic Surgery 2017, 104: 1306-1312. PMID: 28625392, DOI: 10.1016/j.athoracsur.2017.03.013.Peer-Reviewed Original ResearchConceptsPostoperative nutrition supportNutrition supportCardiac surgeryNS scoresAdult cardiac surgery patientsMultivariable logistic regression modelingEarly postoperative nutritionMalnutrition-related morbidityCardiac surgery patientsNovel risk scoreRelative odds ratioLogistic regression modelingTiming of initiationPostoperative nutritionSurgery patientsDerivation cohortIndependent predictorsPredictive screening toolMultivariable analysisValidation cohortC-statisticOdds ratioHigh riskRisk scorePatients
2011
The effects of family stressors on substance use initiation in adolescence
Fletcher JM, Sindelar JL. The effects of family stressors on substance use initiation in adolescence. Review Of Economics Of The Household 2011, 10: 99-114. PMID: 24058324, PMCID: PMC3777731, DOI: 10.1007/s11150-010-9116-z.Peer-Reviewed Original ResearchLikelihood of smokingTiming of initiationFamily stressFamily stressorsPrice of cigarettesControl groupSmokingAlcohol useSubstance useLong-term adverse impactsLongitudinal studyDrinkingComposite measureAdolescenceSimilar stressorsNational panel dataSocio-economic factorsStressorsInitiationStress measures
2010
Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy
Abdool Karim S, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q. Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy. New England Journal Of Medicine 2010, 362: 697-706. PMID: 20181971, PMCID: PMC3076221, DOI: 10.1056/nejmoa0905848.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-Retroviral AgentsAntitubercular AgentsCD4 Lymphocyte CountDrug Administration ScheduleDrug Therapy, CombinationFemaleFollow-Up StudiesHIVHIV InfectionsHumansKaplan-Meier EstimateMaleMiddle AgedPatient ComplianceRNA, ViralTuberculosisViral LoadYoung AdultConceptsSequential therapy groupHuman immunodeficiency virusAntiretroviral therapyRate of deathTuberculosis therapyHIV infectionDaily antiretroviral regimenIntegrated antiretroviral therapyIntegration of tuberculosisStandard tuberculosis therapyPositive sputum smearPrimary end pointSafety Monitoring CommitteeDiagnosis of tuberculosisAcid-fast bacilliTiming of initiationAntiretroviral regimenAdverse eventsHIV servicesImmunodeficiency virusAntiretroviral drugsSputum smearStudy groupPatientsCell count
2009
Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis
Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. British Journal Of Haematology 2009, 147: 561-570. PMID: 19732054, PMCID: PMC2774157, DOI: 10.1111/j.1365-2141.2009.07872.x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge DistributionAge FactorsAgedChildChild, PreschoolDrug Administration ScheduleEnzyme Replacement TherapyFemaleGaucher DiseaseGlucosylceramidaseHumansIncidenceInfantInfant, NewbornMaleMiddle AgedOsteonecrosisRecombinant ProteinsRegistriesSex DistributionSplenectomyTime FactorsYoung AdultConceptsType 1 Gaucher diseaseYear of diagnosisAvascular necrosisIncidence rateEnzyme replacement therapyGaucher RegistryReplacement therapyInternational Collaborative Gaucher Group Gaucher RegistryRisk of AVNGaucher diseaseAdjusted incidence rate ratioInitiation of ERTIndependent risk factorIncidence rate ratiosTiming of initiationRisk factorsHigh riskPatientsDiagnosisTherapyRate ratioSplenectomyRegistryNecrosisIncidenceUsing Basic Science to Design a Clinical Trial: Baseline Characteristics of Women Enrolled in the Kronos Early Estrogen Prevention Study (KEEPS)
Miller VM, Black DM, Brinton EA, Budoff MJ, Cedars MI, Hodis HN, Lobo RA, Manson JE, Merriam GR, Naftolin F, Santoro N, Taylor HS, Harman SM. Using Basic Science to Design a Clinical Trial: Baseline Characteristics of Women Enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Journal Of Cardiovascular Translational Research 2009, 2: 228-239. PMID: 19668346, PMCID: PMC2721728, DOI: 10.1007/s12265-009-9104-y.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultCardiovascular DiseasesDouble-Blind MethodEstradiolEstrogen Replacement TherapyEstrogens, Conjugated (USP)FemaleHumansMiddle AgedProgesteroneProspective StudiesPulse Therapy, DrugResearch DesignRisk AssessmentRisk FactorsSex FactorsTime FactorsTranslational Research, BiomedicalTreatment OutcomeUnited StatesWomen's HealthConceptsKronos Early Estrogen Prevention StudyMenopausal hormone therapyClinical trialsEpidemiological studiesWomen's Health Initiative hormone trialsEstrogen Replacement StudyYears of menopauseCardiovascular disease riskProgression of atherosclerosisDemographics of womenBasic science studiesTiming of initiationMechanism of actionKEEP participantsMHT useBaseline characteristicsHormone therapyProspective trialPrevention StudyHormone trialsCardiovascular diseaseBasic science informationDisease riskParticipant demographicsAdverse effectsTiming of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies
Sterne J, May M, Costagliola D, de Wolf F, Phillips A, Harris R, Funk M, Geskus R, Gill J, Dabis F, Miró J, Justice A, Ledergerber B, Fätkenheuer G, Hogg R, Monforte A, Saag M, Smith C, Staszewski S, Egger M, Cole S. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. The Lancet 2009, 373: 1352-1363. PMID: 19361855, PMCID: PMC2670965, DOI: 10.1016/s0140-6736(09)60612-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCohort StudiesDisease ProgressionDrug Administration ScheduleEuropeFemaleHIV InfectionsHIV-1HumansKaplan-Meier EstimateMaleMiddle AgedNorth AmericaPatient SelectionPractice Guidelines as TopicProportional Hazards ModelsSensitivity and SpecificityTime FactorsTreatment OutcomeConceptsHIV-1-infected patientsCombination antiretroviral therapyCD4 cell countAntiretroviral therapyCombination therapyCohort studyCell countCD4 cell count rangeCD4 cell count thresholdAntiretroviral-naive patientsProspective cohort studyHIV Cohort StudyRates of AIDSStart of treatmentHigh mortality rateAbsence of treatmentTiming of initiationDeath eventsCell count thresholdTherapy groupImmediate initiationPatientsMortality rateTherapyAIDS
1991
"Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease.
Cedarbaum JM, Gandy SE, McDowell FH. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology 1991, 41: 622-9. PMID: 2027475, DOI: 10.1212/wnl.41.5.622.Peer-Reviewed Original ResearchConceptsMotor response fluctuationsLevodopa therapyLevodopa treatmentDisease clinicResponse fluctuationsParkinson's disease clinicDevelopment of dyskinesiaHistory of patientsTiming of initiationPatient populationDisease onsetParkinson's diseaseDyskinesiaYounger ageDementiaPatientsTherapyAdverse consequencesTreatmentDiseaseGreater proportionInitiationDisease diagnosisClinicDiagnosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply